J&J pays $120M to settle charges of deceptive hip-implant marketing

Johnson & Johnson will pay $120 million to resolve allegations that it used deceptive marketing techniques to sell its metal-on-metal hip implants, according to Bloomberg.

Advertisement

The claims, brought by 46 attorneys general, alleged J&J and its DePuy unit wrongly advertised that more than 90 percent of the devices lasted at least five years. European health regulators instead found the survival rates to be around 5 percent.

“Companies should never be allowed to freely mislead the public, especially when there are health concerns involved,” New York Attorney General Letitia James told Bloomberg. “This settlement serves as an important message that deceptive and false medical practices will never be tolerated.”

A spokesperson for the DePuy subsidiary said the company is not admitting liability or misconduct.

The settlement resolves litigation with 46 states.

More articles on legal and regulatory issues:
Walgreens pays $269M to settle billing fraud lawsuits
14 latest healthcare industry lawsuits, settlements
UnitedHealth sues dozens of drug companies for price-fixing

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Reconsider What’s Possible: Enterprise RCM and the Pro-Fee Practice

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Garett Kreitz, Med-MetrixJohn Stefanowicz, Med-Metrix

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.